Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

SSII Announces Participation in Investor Conferences

SS Innovations International, Inc. (NASDAQ: SSII) has announced its participation in two upcoming investor conferences. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, and Dr. Vishwa Srivastava, Chief Executive Officer – Asia Pacific, will be representing the company.

At the UBS Global Healthcare Conference in Palm Beach Gardens, FL on Tuesday, November 11, 2025, the management will be available for one-on-one and small group meetings throughout the day.

Following this, at the Stifel 2025 Healthcare Conference in New York, NY on Wednesday, November 12, 2025, a group presentation is scheduled for 4:40 p.m. Eastern Time. Similar to the previous conference, the management will also be available for one-on-one and small group meetings throughout the day.

A live webcast and replay of the Stifel group presentation will be accessible on the company’s website at https://ssinnovations.com/investor-overview/.

SS Innovations International, Inc. is known for developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary "SSI Mantra" surgical robotic system and its comprehensive suite of "SSI Mudra" surgical instruments, which support a variety of surgical procedures, including robotic cardiac surgery. The company, headquartered in India, plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. As a result of these announcements, the company's shares have moved 2.46% on the market, and are now trading at a price of $9.98. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS